semaglutide oasis 4 trial Tuesday, the FDA announced the approval of 25 mg of Semaglutide, which is The first GLP-1 weight-loss pill:

The Kentuckiana Integrative Medicine team considers our medical approach to weight loss the most realistic and effective program available

While safety within the phase 3 program is sufficient for marketing authorization (although the risk of cardiovascular events should not exceed a hazard ratio of 1.8 according to a guidance document that was released by the FDA at that time), it is the post-marketing phase in which rare adverse events and any other potential safety risks are identified or resolved

Studies showed that it effectively decreased the formation of abnormal crypts in the colon of rats, which are precursors to colorectal cancer, even though when treated with, DMBA, the chemical inducing colon cancer

Results: Nausea, vomiting, diarrhea, and constipation were the most frequently reported GI adverse events, generally dose-dependent and transient

You're not handed off to a rotating cast of providers